SCHEMBL3090836

SCHEMBL3090836

COc1ccc(Cc2nsc3ccc[c]c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.41
EPAS1 Q99814 1/20 0.37
KDR P35968 2/20 0.37
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 2/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
PDE10A Q9Y233 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098415 0.85 POLB (0.33) RAB9ANPC1POLBGAA
SCHEMBL3086646 0.85 MAPT (0.31) LTA4HALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL3084778 0.81 SLC6A4 (0.35) LMNARAB9ANPC1MEN1KMT2A
SCHEMBL3078552 0.73 LTA4H (0.41) LTA4HKDRALDH1A1SMN1; SMN2LMNA
SCHEMBL3091127 0.73 ALDH1A1 (0.44) LTA4HKDRALDH1A1SMN1; SMN2LMNA
SCHEMBL3089243 0.69 LTA4H (0.46) LTA4HALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL2357024 0.66 LTA4H (0.50) LTA4HALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL542478 0.65 LTA4H (0.58) LTA4HALDH1A1SMN1; SMN2LMNAKDM4E
SCHEMBL27884 0.64 LTA4H (0.81) LTA4HALDH1A1SMN1; SMN2LMNACYP2D6
SCHEMBL25986524 0.64 LTA4H (0.81) LTA4HALDH1A1SMN1; SMN2LMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR LTA4H 2233/4885EPAS1 2403/4885KDR 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.